![](images/graphics/blank.gif)
Tumor proportion scores
-
While PD-L1 expression and neutrophil-to-lymphocyte ratio (NLR) are prognostic biomarkers for lung cancer, few studies have considered their interaction. We hypothesized that the product of PD-L1 expression (tumor proportion score) and the NLR (PD-L1×NLR) might be a postoperative prognostic marker refecting the immune microenvironment of lung cancer.
10p
vileonardodavinci
23-12-2023
4
2
Download
-
Pembrolizumab has become an integral first-line therapeutic agent for non-small cell lung cancer (NSCLC), but its potential predictive role in clinical and molecular characteristics remains to be clarified.
17p
visharma
20-10-2023
4
3
Download
-
Pembrolizumab is effective as first-line therapy against advanced non-small cell lung cancer (NSCLC) in patients with programmed death ligand-1 (PD-L1) expression levels ≥50% [1]. However, it is not effective in all patients, and the factors predicting responses among this population remain unknown.
6p
vikuala271
13-06-2020
30
0
Download
-
Detection of programmed cell death ligand-1 (PD-L1) by immunohistochemistry (IHC) has been commonly used to predict the efficacy of treatment with PD-1/PD-L1 inhibitors. However, there is limited literature regarding the reliability of PD-L1 testing using malignant pleural effusion (MPE) cell blocks.
10p
viorochimaru2711
01-06-2020
6
0
Download
CHỦ ĐỀ BẠN MUỐN TÌM
![](images/graphics/blank.gif)